Pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the Annual Report of the Company for the financial ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biogen Pharmachem Industries Ltd (formerly Sun Techno Overseas Ltd), a BSE-listed company engaged in trading of shares and securities, has filed its 30th Annual Report for FY 2024-25 along with the AGM notice. The company reported income from operations of Rs. 1.20 crore but posted a net loss of Rs. 29.27 lakhs as expenses of Rs. 1.49 crore exceeded income. No dividend has been recommended. The 30th AGM is scheduled for September 25, 2025 via video conferencing. Key AGM agenda includes reappointment of statutory auditors M/s Rishi Sekhri and Associates until 2030, appointment of Kelash Bunkar as Whole Time Director & CFO on nil remuneration, appointment of Aman Patel as Independent Director for a 5-year term, and special resolutions to enhance borrowing limits up to Rs. 100 crore and approve investment/loan powers up to Rs. 100 crore under Section 186 of the Companies Act. The paid-up capital is Rs. 65.26 crore against an authorized capital of Rs. 91 crore.
Shareholders should note the company posted a loss and declared no dividend for the year, which is negative for income-focused investors. The proposals to raise borrowing and investment limits to Rs. 100 crore each suggest management is seeking flexibility for future expansion or treasury activity, but given the loss-making operations, this warrants close scrutiny at the AGM. Shareholders should also vote on key matters including auditor reappointment, new director appointments, and the enhanced borrowing authority.